Lancet 2016 Mar 19
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.   

Related Questions

Does the STAMPEDE trial, showing a survival benefit with the addition of docetaxel to standard treatment, change the standard of care for high risk, n...

We are being referred more patients for salvage radiation after this procedure, not sure what the evidence is.

For those of us just transitioning over to hypofractionation, what are reasonable, but conservative, constraints that you use?

Should it be started at the initial diagnosis of bone mets?

In this case, Gleason 5+5 in all cores, clinical T4.

Is there a role of EBRT to the prostate with extended fields to cover the retroperitoneal nodes plus ADT (definitive therapy) or would you treat as ca...

For example, are PET Axumin or PSMA studies being ordered in the upfront setting?